Table 5 A list of the alterations novelly appeared or increased during the lenvatinib treatment and the drugs with estimating effects for the gene alterations in patients with PD at 4 weeks
Gene | Variant_type | Indel_type | Mut_aa | Mut_nt | Patient_ID | Novelly detected or increased | Report | Evidence level | Drug | Estimating effects | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|
ARID1A | Indel | Insertion | A2027fs | C > CA | HG-12 | Increased | ARID1A oncogenic mutation | (CancerVar) | ATR inhibitors | Responsive | PMID:27958275 |
EZH2 inhibitor | Responsive | PMID:25686104 | |||||||||
PARP inhibitor | Responsive | PMID:26069190 | |||||||||
CTNNB1 | SNV |  | G34V | G > T | HG-06 | Increased | CTNNB1 oncogenic mutation | (CancerVar) | Tankyrase inhibitor | Resistant | PMID:23539443 |
SNV |  | S33C | C > G | HG-12 | Increased | ||||||
DDR2 | SNV |  | W778L | G > T | HG-06 | Novelly detected | DDR2 mutant | (CancerVar) | Dasatinib | Sensitive | PMID:22328973 |
ESR1 | SNV |  | R477* | C > T | HG-18 | Novelly detected | ESR1 oncogenic mutation | Late trials: CGI|(CancerVar) | Fluvestrant | Responsive | PMID:27269946 |
Late trials: CGI|(CancerVar) | Exemestane | Resistant | PMID:27269946 | ||||||||
LEVEL_3A:OncoKB | AZD9496 | Â | PMID:27986707|PMID:27269946|PMID:31563959 | ||||||||
LEVEL_3A:OncoKB | Fulvestrant | Â | PMID:27986707|PMID:27269946|PMID:31563959 | ||||||||
TP53 | SNV |  | G245S | C > T | HG-06 | Increased | TP53 G245S | (CancerVar) | AMGMDS3 | Resistance | PMID:25730903 |
SNV |  | C238S | A > T | HG-18 | Novelly detected | TP53 oncogenic mutation | Early trials: CGI|(CancerVar) | Abemaciclib | Resistant | PMID:27217383 | |
Early trials: CGI|(CancerVar) | Cisplatin | Resistant | PMID:27646943 | ||||||||
Early trials: CGI|(CancerVar) | AZD6738 | Responsive | NCT01955668|https://ash.confex.com/ash/2014/webprogram/Paper71027.html | ||||||||
Early trials: CGI|(CancerVar) | Decitabine | Responsive | PMID:27959731 | ||||||||
(CancerVar) | Doxorubicin | Responsive | PMID:27397505 | ||||||||
Gemcitabine | Responsive | PMID:27397505 | |||||||||
Mitomycin C | Responsive | PMID:27397505 | |||||||||
WEE1 inhibitor | Responsive | PMID:25125259|PMID:27998224 | |||||||||
MDM2 inhibitor | Resistant | PMID:23084521|ASCO 2015 (abstr 10,564) | |||||||||
Pramlintide | Responsive | PMID:25409149 | |||||||||
AR | SNV |  | R609K | G > A | HG-22 | Novelly detected | AR mutation | (CancerVar) | Nilutamide|Cyproterone Acetate|Flutamide|Bicalutamide | Resistance | PMID:26000489 |
ATM | SNV |  | R2832H | G > A | HG-22 | Increased | ATM R2832H | LEVEL_1:OncoKB | Olaparib |  | PMID:32343890 |
ATM | SNV |  | G2891D | G > A | HG-22 | Novelly detected | ATM oncogenic mutation | Early trials: CGI|(CancerVar) | Cisplatin | Responsive | PMID:26238431 |
ATM | Early trials: CGI|(CancerVar) | Olaparib | Responsive | ENA 2014 (abstr 8LBA)|PMID:26510020 | |||||||
ATM | (CancerVar) | ATR inhibitor | Responsive | ENA 2015 (abstr A48) | |||||||
ATM | Indel | Insertion | S1905fs | T > TA | HG-22 | Increased | Temozolomide | Responsive | PMID:23960094 | ||
ATM | DNA-PKc inhibitor | Responsive | PMID:23761041 | ||||||||
ATM | PARP inhibitor | Responsive | ENA 2014 (abstr 8LBA) | ||||||||
ATM | LEVEL_4:OncoKB | Olaparib | Â | PMID:20739657|PMID:26510020 | |||||||
NFE2L2 | SNV |  | D29G | T > C | HG-12 | Novelly detected |  |  |  |  |  |
TERT | SNV |  |  | C > G | HG-06 | Increased |  |  |  |  |  |
SNV |  |  | G > A | HG-06 | Increased |  |  |  |  |  |